Life Sciences News Hubb
Advertisement Banner
  • Home
  • what’s new in science
  • Life Science
  • Contact
No Result
View All Result
  • Home
  • what’s new in science
  • Life Science
  • Contact
No Result
View All Result
Gourmet News Hubb
No Result
View All Result
Home Life Science

Learnings From FDA Public Company Advisory Meeting on Skin Lesion Analyzer Technology

admin by admin
August 26, 2022
in Life Science


On July 28, 2022, the U.S. Food and Drug Administration (FDA) will hold a public advisory committee meeting to discuss skin lesion analyzer (SLA) technology and its application to detecting skin cancers in various patient care settings. This meeting of the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee will focus on algorithm-based SLA devices for adjunctive detection of skin lesions, including skin cancers, and stands to provide industry another layer of thinking on FDA’s perspective on artificial intelligence and machine learning (AI/ML) device technologies.

In announcing this meeting, FDA explained that in recent years it has observed an increased interest in SLA devices employing AI/ML. The agency is seeking expert input from the panel on approaches to evaluate the performance of SLA devices, which have a range of technologies and indications.

The committee will discuss and provide recommendations to FDA on: (1) the diagnosing standard, or ground truth, that should be used as a comparison for the performance of diagnostic devices, e.g., histology, consensus opinion of a panel of dermatologists, opinion of a single dermatologist, or other means; (2) acceptable sensitivity and specificity thresholds based on the target diagnosis (melanoma, basal cell carcinoma, squamous cell carcinoma) or intended user (dermatologist, primary care physician, lay user); (3) patient characteristics, including lower or higher incidence populations, that should be tested before marketing; and (4) the balance of increased access with risk mitigation measures that are appropriate when the devices are used by lay people, by populations with very high or very low incidence of melanoma, by populations with low incidence, but high mortality associated with melanoma, or by the target diagnosis/lesion type.

Additionally, on July 29, 2022, the committee will discuss the possible reclassification of two class III, PMA approved computer-aided melanoma detection devices, MelaFind (P090012) and Nevisense (P150046), both of which are intended for use on cutaneous lesions suspicious for melanoma when a dermatologist chooses to obtain additional information when considering biopsy. According to the FDA announcement, “The committee will discuss if there is sufficient information to reclassify computer-aided devices for adjunctive diagnostic information of lesions suspicious for melanoma from class III to class II, and what special controls may be appropriate to provide reasonable assurance of safety and effectiveness” if they are reclassified.

This meeting, and any actions the FDA takes as a result, could offer industry further insight into the FDA’s approach to regulating AI/ML diagnostic and screening products more broadly.

The meeting will be held virtually on July 28, 2022, from 9 am to 5:45 pm ET and July 29, 2022, 9 am to 4 pm ET. Comments received on or before July 11, 2022 will be provided to the committee and the public docket will remain open for comment for FDA’s consideration until August 29, 2022.

For more information see the Meeting Notice on the Federal Register.



Source link

Tags: fdahealth carenevisensetechnology
Previous Post

False Claims Act Used to Target Private Equity Firms Invested In Healthcare and Life Sciences

Next Post

See the Top Entries in the Art of Neuroscience Competition

Next Post

See the Top Entries in the Art of Neuroscience Competition

Recommended

Senior Editorial Assistant

1 month ago

How to Measure Ripples in Spacetime

4 weeks ago

Mental Health Apps Won’t Get You Off the Couch

3 weeks ago

ASEAN-India Collaborative R&D Scheme – IndiaBioscience

3 months ago

Use Screens to Calm Your Kid Down? Study on Lasting Effects Has Some Troubling News : ScienceAlert

2 months ago

Humans Are Revisiting the Moon—and the Rules of Spacefaring

5 months ago

Life-Sciences-(-White-)

© 2022 Life Sciences News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • what’s new in science
  • Life Science
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • what’s new in science
  • Life Science
  • Contact

© 2022 Life Sciences News Hubb All rights reserved.